GLUE
Monte Rosa Therapeutics Inc

1,499
Mkt Cap
$1.81B
Volume
1.28M
52W High
$25.77
52W Low
$3.50
PE Ratio
77.64
GLUE Fundamentals
Price
$24.44
Prev Close
$23.71
Open
$23.05
50D MA
$16.93
Beta
1.55
Avg. Volume
1.12M
EPS (Annual)
-$0.9836
P/B
5.96
Rev/Employee
$564,343.28
Loading...
Loading...
News
all
press releases
Short Interest in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Rises By 20.7%
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) saw a large growth in short interest during the month of December. As of December 31st, there was short interest totaling 8,454,052...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Recommendation of "Moderate Buy" by Brokerages
Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the eight brokerages that are currently covering the firm...
MarketBeat·10d ago
News Placeholder
Monte Rosa Therapeutics (NASDAQ:GLUE) CEO Markus Warmuth Sells 5,466 Shares
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) CEO Markus Warmuth sold 5,466 shares of the business's stock in a transaction on Wednesday, January 7th. The shares were sold at an...
MarketBeat·11d ago
News Placeholder
GLUE Stock Slips Pre-Market After Pricing $300 Million Public Offer At Discount
The offering includes 11.125 million shares of common stock priced at $24.00 per share, a 5.1% discount to Thursday’s close at $25.31.
Stocktwits·11d ago
News Placeholder
Nasdaq, S&P 500 Futures Pause Ahead Of Jobs Report, Trump Tariff Ruling: Why OPEN, INTC, NVDA, TLRY, CRMD Are On Traders' Radar Today
Early signals show futures flat, SPY sentiment cooling, and tech traders turning bullish.
Stocktwits·12d ago
News Placeholder
GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug
Monte Rosa shares surge 45% after interim phase I data show that MRT-8102 drives deep NEK7 degradation and reduces sharp inflammation markers.
Zacks·12d ago
News Placeholder
Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says
Wells Fargo & Company lifted their price target on Monte Rosa Therapeutics from $22.00 to $30.00 and gave the company an "overweight" rating in a report on Thursday...
MarketBeat·12d ago
News Placeholder
Monte Rosa Therapeutics (NASDAQ:GLUE) Given New $34.00 Price Target at Guggenheim
Guggenheim increased their target price on shares of Monte Rosa Therapeutics from $16.00 to $34.00 and gave the company a "buy" rating in a research note on Thursday...
MarketBeat·12d ago
News Placeholder
Monte Rosa Therapeutics (GLUE) is on the Move, Here's Why the Trend Could be Sustainable
Monte Rosa Therapeutics (GLUE) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Zacks·12d ago
News Placeholder
Monte Rosa Therapeutics (GLUE) Upgraded to Strong Buy: Here's Why
Monte Rosa Therapeutics (GLUE) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·13d ago
<
1
2
...
>

Latest GLUE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.